Physicochemical and biological characterization of GNR-087, a Tocilizumab biosimilar, Journal of Pharmaceutical and Biomedical Analysis, Volume 273, 2026, 117407, ISSN 0731-7085
2026
Complarate®
INN: tocilizumab
Description
Indications for use
Instruction
Articles for specialists
Tocilizumab is a genetically engineered biological drug, the first interleukin 6 (IL6) receptor inhibitor registered for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.
Tocilizumab helps curb systemic inflammatory responses and is currently used to treat severe conditions such as COVID-19 and life-threatening cytokine release syndrome.
It is a humanized monoclonal antibody to the human interleukin-6 receptor from the IgG1 immunoglobulin subclass, which, by binding to mIL6R and rIL6R, inhibits both signaling pathways of IL6-dependent cellular activation.
Research and experience in real medical practice confirm the high efficacy and well-studied safety profile of tocilizumab.
- Rheumatoid arthritis (RA) with moderate or high activity in adults, both as monotherapy and in combination with methotrexate (MT) and/or with other disease-modifying anti-inflammatory drugs (DMARDs), including for inhibition of radiologically proven joint destruction.
- Active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years and older, both as monotherapy and in combination with MTX.
- Active systemic juvenile idiopathic arthritis (sJIA) in patients aged 2 years and older, both as monotherapy and in the case of MTX.
- Treatment COVID-19 in hospitalized adult patients receiving systemic corticosteroids who require oxygen support or mechanical ventilation.
- Severe or life-threatening cytokine release syndrome induced by chimeric antigen receptor (CAR) T-cell preparations in adult patients.
-
Read